- Home
- DMA vs SKYE Comparison
DMA vs SKYE Comparison
Compare DMA & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMA
- SKYE
- Stock Information
- Founded
- DMA 2011
- SKYE 2012
- Country
- DMA United States
- SKYE United States
- Employees
- DMA N/A
- SKYE N/A
- Industry
- DMA Trusts Except Educational Religious and Charitable
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- DMA Finance
- SKYE Health Care
- Exchange
- DMA Nasdaq
- SKYE Nasdaq
- Market Cap
- DMA 70.8M
- SKYE 80.7M
- IPO Year
- DMA N/A
- SKYE N/A
- Fundamental
- Price
- DMA $7.99
- SKYE $1.73
- Analyst Decision
- DMA
- SKYE Buy
- Analyst Count
- DMA 0
- SKYE 6
- Target Price
- DMA N/A
- SKYE $16.60
- AVG Volume (30 Days)
- DMA 34.6K
- SKYE 1.7M
- Earning Date
- DMA 01-01-0001
- SKYE 05-09-2025
- Dividend Yield
- DMA 2.04%
- SKYE N/A
- EPS Growth
- DMA N/A
- SKYE N/A
- EPS
- DMA N/A
- SKYE N/A
- Revenue
- DMA N/A
- SKYE N/A
- Revenue This Year
- DMA N/A
- SKYE N/A
- Revenue Next Year
- DMA N/A
- SKYE N/A
- P/E Ratio
- DMA N/A
- SKYE N/A
- Revenue Growth
- DMA N/A
- SKYE N/A
- 52 Week Low
- DMA $4.78
- SKYE $1.14
- 52 Week High
- DMA $8.00
- SKYE $16.01
- Technical
- Relative Strength Index (RSI)
- DMA 45.67
- SKYE 49.29
- Support Level
- DMA $7.71
- SKYE $1.36
- Resistance Level
- DMA $8.05
- SKYE $3.73
- Average True Range (ATR)
- DMA 0.33
- SKYE 0.35
- MACD
- DMA 0.03
- SKYE 0.07
- Stochastic Oscillator
- DMA 65.60
- SKYE 22.81
About DMA Destra Multi-Alternative Fund
Destra Multi-Alternative Fund is a non-diversified, closed-end management investment company that operates as an interval fund with a continuous offering of fund shares. The investment objective of the fund is to seek returns from capital appreciation and income with an emphasis on income generation.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.